• 2014 - 2017 İstanbul Kartal Lütfi Kırdar Eğitim ve Araştırma Hastanesi Yandal Uzmanlık
• 2009 - 2013 İzmir Atatürk Eğitim ve Araştırma Hastanesi Uzmanlık Eğitimi 
• 2002 - 2008 Dicle Üniversitesi Tıp Fakültesi

• Kişiye Özel Akıllı İlaç Tedavisi
• İmmünoterapiler
• Akciğer Kanseri
• Meme Kanseri
• Bağırsak Kanseri ( Kolorektol kanserler)
• Prostat Kanseri
• Mide ve Yemek Borusu Kanseri
• Böbrek ve İdrar Kesesi Kanseri
• Kadın Doğum Kanserleri
• Beyin, Baş ve Boyun Kanserleri
• Kanserde Beslenme ve Destek Tedavileri

• 2023 - 2026 KARTAL DR. LÜTFİ KIRDAR ŞEHİR HASTANESİ
• 2019 - 2023 VM MEDICAL PARK KOCAELİ HASTANESİ
• 2017 - 2019 GAZİANTEP DR. ERSİN ARSLAN EĞİTİM ARAŞTIRMA HASTANESİ
• 2013 - 2014 BATMAN BÖLGE DEVLET HASTANESİ
• 2008 - 2009 DİYARBAKIR 5 NOLU 112 SAĞLIK HİZMETLERİ İSTASYONU

Ulusal Makaleler

2025

• Altıntaş YE, Kınıkoğlu O, Işık D ve ark. Very Favorable vs. Favorable Risk Groups in Metastatic Renal Cell Carcinoma: A Step Toward Personalized Treatment. Cancers, 2025. (Q1)
• Kınıkoğlu O, Işık D. Evaluating the Performance of ChatGPT-4o Oncology Expert in Comparison to Standard Medical Oncology Knowledge: A Focus on Treatment-Related Clinical Questions. Cureus, 2025.
• Topal A, Akdağ G, Yıldırım S, Işık D ve ark. Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study. Medicina, 2025. (Q1)

2024

• Işık D, Kınıkoğlu O. Prognostic and Molecular Characterization of Metastatic Transverse Colon Cancer: Insights From a Single-Center Retrospective Study. Cureus, 2024.
• Kınıkoğlu O, Odabaş H, Altıntaş YE, Işık D ve ark. Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer. Medicina, 2024. (Q1)
• Yıldırım S, Doğan A, Akdağ G, Işık D ve ark. The Role of Laboratory Indices on Treatment Response and Survival in Breast Cancer Receiving Neoadjuvant Chemotherapy. Scientific Reports, 2024. (Q1)
• Kahraman S, Karakaya S, Kaplan MA, Işık D ve ark. Treatment Outcomes and Prognostic Factors in Patients with Driver Mutant Non-Small Cell Lung Cancer and De Novo Brain Metastases. Scientific Reports, 2024. (Q1)
• Akdağ G, Alan Ö, Doğan A, Işık D ve ark. Prognostic Scores in Pulmonary Large Cell Neuroendocrine Carcinoma: A Retrospective Cohort Study. Heliyon, 2024. (Q1)
• Akdağ G, Doğan A, Yıldırım S, Işık D ve ark. Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer. Cureus, 2024.
• Kahraman S, Hizal M, Işık D ve ark. Activity of CDK4/6 Inhibitors and Parameters Affecting Survival in Elderly Patients. BMC Cancer, 2024. (Q2)
• Yıldırım S, Doğan A, Akdağ G, Işık D ve ark. Lymphocyte-to-Albumin Ratio Predicts Survival in Metastatic NSCLC Patients. Cancers, 2024. (Q1)
• Akdağ G, Alan Ö, Doğan A, Işık D ve ark. Efficacy and Safety of Ixabepilone in Metastatic Breast Cancer After Multiple Treatments. Journal of Oncological Sciences, 2024.
• Altıntaş YE, Kınıkoğlu O, Yıldız A, Işık D ve ark. Trastuzumab Rechallenge in HER2-Positive Metastatic Breast Cancer. Medicina, 2024. (Q1)
• Işık D, Alan Ö, Akdağ G ve ark. Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older. Journal of Clinical Medicine, 2024. (Q1)
• Yıldırım S, Alan Ö, Yüksel YZ, Işık D ve ark. Prognostic Impact and Clinical Features of Spread Through Air Spaces in Operated Lung Cancer. Medicina, 2024. (Q1)
• Akdağ G, Işık D, Doğan A ve ark. Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer? Medicina, 2024. (Q1)
• Işık D, Kınıkoğlu O, Akdağ G ve ark. Clinical Effectiveness of Targeted Therapies Following Nivolumab Therapy in Metastatic Renal Cell Carcinoma. Medicina, 2024. (Q1)
• Gürler F, Tay F, Işık D ve ark. Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma. Cancer Medicine, 2024. (Q2)
• Akdağ G, Yıldırım S, Doğan A, Işık D ve ark. Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2− Breast Cancer. Chemotherapy, 2024. (Q3)

2023 ve Öncesi

• Işık D, Koca D. XLOT Regimen Instead of FLOT Regimen in Gastric Cancer. Journal of Cancer Research and Therapeutics, 2023.
• Kahraman S, Urul E, Işık D ve ark. Treatment Efficacy of Ribociclib or Palbociclib Plus Letrozole in Metastatic Breast Cancer. Future Oncology, 2023.
• Karaçin C, Işık D ve ark. Efficacy of Subsequent Treatments in Patients with Hormone-Positive Advanced Breast Cancer. BMC Cancer, 2023.
• Bahçeci A, Paydaş S, Işık D ve ark. Efficacy and Safety of Trastuzumab Emtansine in HER2 Positive Metastatic Breast Cancer. Cancer Investigation, 2021.
• Bahçeci A, Kötek SA, Işık D. The Prognostic Values of Prognostic Nutritional Index in Extensive-Stage Small Cell Lung Cancer. Anti-Cancer Drugs, 2021.
• Kefeli U, Kaymaz S, Aydın D, Işık D ve ark. Adjuvant Chemotherapy in Elderly Patients with Early-Stage Non-Small Cell Lung Cancer. Bezmialem Science, 2019.
• Aydın D, Şendur MA, Işık D ve ark. Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma. Clinical Colorectal Cancer, 2017.
• Özçelik M, Korkmaz T, Odabaş H, Işık D ve ark. Comparison of Chemotherapy Regimens in Inoperable Stage III Non-Small Cell Lung Cancer. Tumor Biology, 2016.
• Aydın D, Bilici A, Yavuzer D, Işık D ve ark. Prognostic Significance of ADAM17 Expression in Gastric Cancer. Clinical & Translational Oncology, 2015.
• Özçelik M, Odabaş H, Işık D ve ark. Capecitabine Plus Bevacizumab Combination in Elderly Metastatic Colorectal Cancer Patients. Clinical & Translational Oncology, 2015.

Uluslararası Makaleler

• Efficacy and Safety of CDK4/6 Inhibitor Therapy in Patients Aged 70 and Older with Metastatic Breast Cancer: A Retrospective Single Center Analysis. Southern Clinics of Istanbul Eurasia, 2025.
• The Clinical Significance of Fibrinogen-Like Protein 2 (FGL-2) Levels in Nonalcoholic Steatohepatitis. Southern Clinics of Istanbul Eurasia, 2024.
• The Prevalence and Prognostic Relevance of ABO/Rh Blood Groups in Metastatic Breast Cancer Patients Undergoing CDK4/6 Inhibitor Therapy. Eurasian Journal of Medical Investigation, 2024.
• Factors Affecting Recurrence in Transverse Colon Tumors: A Single-Center Study. Southern Clinics of Istanbul Eurasia, 2024.
• Male Breast Cancer in a Single-Center Experience: Diagnosis, Clinicopathological Features and Treatment Strategies. İstanbul Kuzey Klinikleri, 2024.

Kitap Bölümleri

• Onkolojide Güncel Tedavi Yaklaşımları (2019) – Tiroid Kanserlerinde Tirozin Kinaz İnhibitör Tedavisi
• Gastrointestinal Sistem Tümörleri-1 (2019) – Metastatik Mide Kanserinde Moleküler Hedefli Tedaviler
• Onkoloji (2018) – Jinekolojik Kanserler

Bilimsel Kongre ve Bildiriler

• 10. Multidisipliner Baş Boyun Kanserleri Kongresi (2025)
  5. Meme Kanseri Sempozyumu (2025)
  2. Onkolojide Yenilikler Sempozyumu (2024)
•      Onkolojide Yenilikler Sempozyumu (2023)
  10. Türk Tıbbi Onkoloji Kongresi (2023)